About: Inhibition of enterovirus 71 replication and the viral 3D polymerase by aurintricarboxylic acid

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Inhibition of enterovirus 71 replication and the viral 3D polymerase by aurintricarboxylic acid Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Inhibition of enterovirus 71 replication and the viral 3D polymerase by aurintricarboxylic acid
Creator	Shih, Shin-Ru Hung, Hui-Chen Hsu, T.-A Tseng, Ching-Ping Hsu, -A Chen, Tzu-Chun Fang, Ming-Yu Yen, Kuei-Jung
Source	Medline; PMC
abstract	OBJECTIVES: Enterovirus 71 (EV71) causes serious diseases in humans. The aim of this study was to examine the effects of aurintricarboxylic acid (ATA) on EV71 replication and to explore the underlying mechanism. METHODS: To measure the activity of ATA in inhibiting the cytopathic effect (CPE) of EV71, a cell-based neutralization (inhibition of virus-induced CPE) assay was performed. The effect of ATA was further confirmed using plaque reduction and viral yield reduction assays. A time of addition assay was performed to identify the mechanisms of ATA's anti-EV71 activity. We examined the effects of ATA on the following key steps involved in virus replication: (i) translation of the internal ribosomal entry site (IRES)-mediated viral polyprotein; (ii) the proteolytic activity of viral proteases 2A and/or 3C; and (iii) the viral 3D RNA-dependent RNA polymerase (RdRp) activity. RESULTS: In this study, ATA was found to be a potent inhibitor of the replication of EV71. In the antiviral neutralization assay, ATA exhibited inhibitory activity against EV71 (TW/4643/98) and EV71 (TW/2231/98). Plaque assay further demonstrated that ATA inhibited EV71 replication with an EC(50) (effective concentration at which 50% of plaques were removed) of 2.9 µM. Studies on the mechanism of action revealed that ATA targets the early stage of the viral life cycle after viral entry. ATA was able to inhibit the RdRp activity of EV71, while neither the IRES-mediated translation of viral polyprotein nor the viral 3C protease activity was affected. CONCLUSIONS: Overall, the findings in this study suggest that ATA is able to effectively inhibit EV71 replication through interfering with the viral 3D polymerase.
has issue date	2010-01-20(xsd:dateTime)
bibo:doi	10.1093/jac/dkp502
bibo:pmid	20089540
has license	no-cc
sha1sum (hex)	44290ff75bad8ffaf5d3028420739ce7b08dc2a9
schema:url	https://doi.org/10.1093/jac/dkp502
resource representing a document's title	Inhibition of enterovirus 71 replication and the viral 3D polymerase by aurintricarboxylic acid
has PubMed Central identifier	PMC7110181
has PubMed identifier	20089540
schema:publication	J Antimicrob Chemother
resource representing a document's body	covid:44290ff75bad8ffaf5d3028420739ce7b08dc2a9#body_text
is schema:about of	named entity 'INHIBITION' covid:arg/44290ff75bad8ffaf5d3028420739ce7b08dc2a9 named entity 'STUDY' named entity 'EFFECTS' named entity 'REPLICATION' named entity 'AIM' named entity 'EV71' named entity 'HUMANS' named entity 'MECHANISM' named entity 'ENTEROVIRUS 71' named entity 'TO EXAMINE' named entity 'AURINTRICARBOXYLIC ACID' named entity 'POLYMERASE' named entity 'REPLICATION' named entity 'VIRAL' named entity 'DISEASES' named entity 'CAUSES' named entity 'AURINTRICARBOXYLIC ACID' named entity 'UNDERLYING' named entity 'diseases' named entity 'polymerase' named entity 'infection' named entity 'Vero cells' named entity 'culture medium' named entity 'Inhibition' named entity 'replication' named entity 'EV71' named entity 'diseases in humans' named entity 'aurintricarboxylic acid' named entity 'incubation' named entity 'EV71' named entity 'hepatitis C virus' named entity 'Renilla luciferase' named entity 'pFLAG' named entity 'enterovirus' named entity 'cell lysis' named entity 'viral replication' named entity 'Vero' named entity 'coxsackievirus' named entity 'isopropanol' named entity 'HCV' named entity 'sodium phosphate' named entity 'mCi' named entity 'infection' named entity 'cell culture' named entity 'polymerase' named entity 'cellular functions' named entity 'DMEM' named entity 'infection' named entity 'COS-7' named entity 'virus' named entity 'internal control' named entity 'virus' named entity 'virus infection' named entity 'IRES' named entity 'plaque assay' named entity 'inoculated' named entity 'antisense' named entity 'plasmid' named entity 'cell lysates' named entity 'DMEM' named entity 'Renilla luciferase' named entity 'transfection' named entity 'virus' named entity 'cell-based' named entity 'virus replication cycle' named entity 'SARS-CoV' named entity 'Vero' named entity 'Renilla luciferase' named entity 'DMSO' named entity 'transfection' named entity 'echovirus' named entity 'firefly luciferase' named entity 'polyprotein'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software